Cytologic features of well differentiated G3 pancreatic neuroendocrine tumors

被引：0
|
作者：
Sigel, Carlie S. [1 ]
Silva, Vitor Werneck Krauss [1 ]
Reid, Michelle [2 ]
Chhieng, David [3 ]
Sigel, Keith [4 ]
Basturk, Olca [5 ]
Daniel, Tanisha [6 ]
Klimstra, David [7 ]
Tang, Laura [8 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] MSKCC, New York, NY USA
[6] Univ Med & Dent New Jersey, New Brunswick, NJ USA
[7] Mem Sloan Kettering, New York, NY USA
[8] Mem Sloan Kettering CC, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
485
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [1] Cytologic features of well differentiated G3 pancreatic neuroendocrine tumors
    Sigel, Carlie S.
    Silva, Vitor Werneck Krauss
    Reid, Michelle
    Chhieng, David
    Sigel, Keith
    Basturk, Olca
    Daniel, Tanisha
    Klimstra, David
    Tang, Laura
    MODERN PATHOLOGY, 2018, 31 : 175 - 175
  • [2] Treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3)
    Apostolidis, L.
    Jaeger, D.
    Winkler, E. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors
    Mohamad Bassam Sonbol
    Thorvardur R. Halfdanarson
    Current Treatment Options in Oncology, 2019, 20
  • [4] Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors
    Sonbol, Mohamad Bassam
    Halfdanarson, Thorvardur R.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (09)
  • [5] Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3
    Hinterleitner, Martina
    Pfeiffer, Ruben
    Trautwein, Nils F.
    Sipos, Bence
    Singer, Stephan
    Nadalin, Silvio
    Koenigsrainer, Alfred
    Lauer, Ulrich M.
    la Fougere, Christian
    Zender, Lars
    Hinterleitner, Clemens
    FRONTIERS IN ENDOCRINOLOGY, 2024, 14
  • [6] Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate
    Tanaka H.
    Matsusaki S.
    Baba Y.
    Isono Y.
    Kumazawa H.
    Sase T.
    Okano H.
    Saito T.
    Mukai K.
    Kaneko H.
    Clinical Journal of Gastroenterology, 2015, 8 (6) : 414 - 420
  • [7] Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) G3: Does the Ki67 Really Do It All?
    Cros, J.
    Soukeur, M.
    Raffenne, J.
    Florent, D.
    De Montpreville, Thomas V.
    Antoine, M.
    Scoazec, J. Y.
    Cazes, A.
    Svrcek, M.
    Hentic, O.
    Sauvanet, A.
    Bedossa, P.
    Paradis, V.
    Ruszniewski, P.
    Couvelard, A.
    NEUROENDOCRINOLOGY, 2016, 103 : 6 - 6
  • [8] G3 Neuroendocrine Neoplasms (G3 NENs) with Deceptively Well-Differentiated Histologic Features Have a Poor Outcome
    Jih, Lily
    Mertens, Richard
    Yu, Run
    Wolin, Edward
    Dhall, Deepti
    PANCREAS, 2013, 42 (02) : 376 - 376
  • [9] Multicenter analysis of treatment outcomes for well differentiated grade 3 neuroendocrine tumors (NET G3).
    Apostolidis, Leonidas
    Dal Buono, Arianna
    Merola, Elettra
    Jann, Henning
    Jaeger, Dirk
    Wiedenmann, Bertram
    Winkler, Eva Caroline
    Pavel, Marianne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Clinical Characteristics and Treatment Outcome of Six Advanced G3 Well-Differentiated Neuroendocrine Tumors
    Jia, R.
    Chen, H. E.
    Chen, Y. L.
    Ge, F. J.
    Liu, R. R.
    Li, S. S.
    Zhao, C. H.
    Liu, L. J.
    Sun, M. F.
    Zhang, Y.
    Wang, Y.
    Lin, L.
    Xu, J. M.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 119 - 119
12345